IPSEN |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121.7 EUR | +0.75% |
|
+2.27% | +12.79% |
| 05-14 | Ipsen: share price up, analyst raises target | CF |
| 05-14 | IPSEN : Barclays raises its target price | CF |
ETFs positioned on Ipsen
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 234 M€ | +6.81% | - | |
| 0.00% | 306 M€ | +6.54% | - | |
| 0.00% | 39 M€ | +6.43% | - | |
| 0.00% | 1 M€ | 0.00% | - | |
| 0.00% | 29 M€ | 0.00% | - | |
| 0.00% | 146 M€ | -2.01% | - | |
| 0.00% | 25 M€ | -2.62% | - |
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
28/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
121.7
EUR
Average target price
126.3
EUR
Spread / Average Target
+3.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.79% | 10.85B | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| +14.11% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B |
- Stock Market
- Equities
- IPN Stock
- Funds and ETFs Ipsen
